Prognostic value of secreted phosphoprotein-1 in pleural effusion associated with non-small cell lung cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Zhang, He ^a,b   Liu, Hong bing ^a   Yuan, Dong mei ^a   Wang, Zhao feng ^a   Wang, Yun fen ^a   Song, Yong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

Author keywords

Non small cell lung cancer; Osteopontin; Prognosis; Secreted phosphoprotein 1; Wmalignant pleural effusion

Indexed keywords

PHOSPHOPROTEIN; PHOSPHOPROTEIN 1; UNCLASSIFIED DRUG; OSTEOPONTIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRAPULMONARY METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; VERY ELDERLY; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OSTEOPONTIN; PROGNOSIS;

EID: 84900341825     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-280     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30. 10.3322/caac.21166, 23335087.
2. Lu X, Fang Y, Wang Z, Xie J, Zhan Q, Deng X, Chen H, Jin J, Peng C, Li H, Shen B. Downregulation of gas5 increases pancreatic cancer cell proliferation by regulating CDK6. Cell Tissue Res 2013, 354(3):891-896. 10.1007/s00441-013-1711-x, 24026436.
3. Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion. Chest 2006, 129(2):362-368. 10.1378/chest.129.2.362, 16478853.
4. Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 1997, 3(1):47-50.
5. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008, 83(2):235-250. 10.1016/S0025-6196(11)60848-3, 18241636.
6. Gu P, Huang G, Chen Y, Zhu C, Yuan J, Sheng S. Diagnostic utility of pleural fluid carcinoembryonic antigen and CYFRA 21-1 in patients with pleural effusion: a systematic review and meta-analysis. J Clin Lab Anal 2007, 21(6):398-405. 10.1002/jcla.20208, 18022924.
7. Liang QL, Shi HZ, Qin XJ, Liang XD, Jiang J, Yang HB. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. Thorax 2008, 63(1):35-41. 10.1136/thx.2007.077958, 17573438.
8. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A 1986, 83(23):8819-8823. 10.1073/pnas.83.23.8819, 387024, 3024151.
9. Heinegard D, Hultenby K, Oldberg A, Reinholt F, Wendel M. Macromolecules in bone matrix. Connect Tissue Res 1989, 21(1-4):3-11. discussion 12-14.
10. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995, 72(1):55-63.
11. Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 2006, 16(2):79-87. 10.1016/j.tcb.2005.12.005, 16406521.
12. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, Bulbule A, Kale S, Kumar S, Mishra R, Raja R, Saraswati S, Kaur R, Soundararajan G, Kumar D, Thorat D, Sanyal M, Ramdasi A, Ghosh P, Kundu GC. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets 2011, 15(9):1113-1126. 10.1517/14728222.2011.594438, 21718227.
13. Rittling SR, Chen Y, Feng F, Wu Y. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002, 277(11):9175-9182. 10.1074/jbc.M109028200, 11741994.
14. Ue T, Yokozaki H, Kitadai Y, Yamamoto S, Yasui W, Ishikawa T, Tahara E. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 1998, 79(2):127-132. 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V, 9583725.
15. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001, 7(12):4060-4066.
16. Chuang CY, Chang H, Lin P, Sun SJ, Chen PH, Lin YY, Sheu GT, Ko JL, Hsu SL, Chang JT. Up-regulation of osteopontin expression by aryl hydrocarbon receptor via both ligand-dependent and ligand-independent pathways in lung cancer. Gene 2012, 492(1):262-269. 10.1016/j.gene.2011.10.019, 22037483.
17. Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, Unnoura T, Iwakami S, Hirama M, Ishiwata T, Iwase A, Takahashi K. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 2009, 63(3):368-374. 10.1016/j.lungcan.2008.06.020, 18752867.
18. Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, Kollintza A, Simoes DC, Kardara M, Vassiliou S, Papiris SA, Roussos C, Kalomenidis I. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. Oncogene 2013, 32(4):528-535. 10.1038/onc.2012.57, 22370646.
19. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147(2):275-292. 10.1016/j.cell.2011.09.024, 3261217, 22000009.
20. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005, 11(13):4646-4652. 10.1158/1078-0432.CCR-04-2013, 16000556.
21. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Holscher AH, Danenberg PV. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004, 10(5):1588-1596. 10.1158/1078-0432.CCR-0565-3, 15014008.
22. Donati V, Boldrini L, Dell'Omodarme M, Prati MC, Faviana P, Camacci T, Lucchi M, Mussi A, Santoro M, Basolo F, Fontanini G. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005, 11(18):6459-6465. 10.1158/1078-0432.CCR-05-0541, 16166420.
23. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN, Franklin WA, Le QT, Crowley JJ, Gandara DR. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008, 26(29):4771-4776. 10.1200/JCO.2008.17.0662, 2653139, 18779603.
24. Elsammak MM, Morsi TS, Khamis HI, Ragab MS, Zaki MA, Abdel-Hadi M, Hassan HA. Osteopontin and C-reactive protein in Egyptian patients affected with tuberculous and malignant pleural effusion. Ann Clin Biochem 2007, 44(Pt 3):264-272.
25. Moschos C, Porfiridis I, Psallidas I, Kollintza A, Stathopoulos GT, Papiris SA, Roussos C, Kalomenidis I. Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology 2009, 14(5):716-722. 10.1111/j.1440-1843.2009.01536.x, 19476604.
26. O'Regan A. The role of osteopontin in lung disease. Cytokine Growth Factor Rev 2003, 14(6):479-488. 10.1016/S1359-6101(03)00055-8, 14563350.
27. Inomata S, Shijubo N, Kon S, Maeda M, Yamada G, Sato N, Abe S, Uede T. Circulating interleukin-18 and osteopontin are useful to evaluate disease activity in patients with tuberculosis. Cytokine 2005, 30(4):203-211. 10.1016/j.cyto.2005.01.014, 15863395.